<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral steroids for long‐term use in cystic fibrosis - Cheng, K - 2015 | Cochrane Library</title> <meta content="Oral steroids for long‐term use in cystic fibrosis - Cheng, K - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000407.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral steroids for long‐term use in cystic fibrosis - Cheng, K - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000407.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000407.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Oral steroids for long‐term use in cystic fibrosis" name="citation_title"/> <meta content="Katharine Cheng" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="kcheng31@its.jnj.com" name="citation_author_email"/> <meta content="Deborah Ashby" name="citation_author"/> <meta content="Imperial College London" name="citation_author_institution"/> <meta content="Rosalind L Smyth" name="citation_author"/> <meta content="UCL" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD000407.pub4" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/12/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000407.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000407.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000407.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Anti-Inflammatory Agents [*administration &amp; dosage, adverse effects]; Cystic Fibrosis [*complications]; Early Termination of Clinical Trials; Glucocorticoids [*administration &amp; dosage, adverse effects]; Growth [drug effects]; Prednisolone [administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic; Respiratory Tract Diseases [*drug therapy, etiology]; Sex Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000407.pub4&amp;doi=10.1002/14651858.CD000407.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000407\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000407\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000407.pub4",title:"Oral steroids for long\\u2010term use in cystic fibrosis",firstPublishedDate:"Dec 9, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Cystic Fibrosis and Genetic Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000407.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000407.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000407.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000407.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000407.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000407.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000407.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000407.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000407.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000407.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1768 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000407.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/full#CD000407-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/full#CD000407-sec-0062"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/full#CD000407-sec-0008"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/full#CD000407-sec-0012"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/full#CD000407-sec-0013"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/full#CD000407-sec-0035"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/full#CD000407-sec-0061"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/table_n/CD000407StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/table_n/CD000407StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2015 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral steroids for long‐term use in cystic fibrosis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/information#CD000407-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Katharine Cheng</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/information#CD000407-cr-0005">Deborah Ashby</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000407.pub4/information#CD000407-cr-0006">Rosalind L Smyth</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/information/en#CD000407-sec-0070">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 December 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000407.pub4">https://doi.org/10.1002/14651858.CD000407.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000407-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000407-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000407-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000407-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000407-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000407-abs-0001" lang="en"> <section id="CD000407-sec-0001"> <h3 class="title" id="CD000407-sec-0001">Background</h3> <p>In cystic fibrosis (CF) airway obstruction and recurrent respiratory infection lead to inflammation, long‐term lung damage, respiratory failure and death. Anti‐inflammatory agents, e.g. oral corticosteroids are used since inflammation occurs early in disease. This is an update of a previously published review. </p> </section> <section id="CD000407-sec-0002"> <h3 class="title" id="CD000407-sec-0002">Objectives</h3> <p>To assess the effectiveness of oral corticosteroids in respiratory complications in CF, particularly lung function and adverse events. We examined long‐term use (over 30 days) only. </p> </section> <section id="CD000407-sec-0003"> <h3 class="title" id="CD000407-sec-0003">Search methods</h3> <p>We searched the Cochrane CF and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. </p> <p>Most recent search: 28 August 2015.</p> </section> <section id="CD000407-sec-0004"> <h3 class="title" id="CD000407-sec-0004">Selection criteria</h3> <p>Randomised trials comparing oral corticosteroids given for more than 30 days with placebo or no additional therapy in people with CF. </p> </section> <section id="CD000407-sec-0005"> <h3 class="title" id="CD000407-sec-0005">Data collection and analysis</h3> <p>Two authors independently assessed study eligibility and quality.</p> </section> <section id="CD000407-sec-0006"> <h3 class="title" id="CD000407-sec-0006">Main results</h3> <p>Of eleven studies identified, three (354 participants) were included: two with four‐year follow up and one with 12‐weeks follow up. Data were lacking on predefined outcomes; common outcomes were examined at different time‐points and presented differently. Meta‐analyses were not possible. </p> <p>In one study, oral corticosteroids at prednisolone‐equivalent dose of 1 mg/kg alternate days slowed progression of lung disease; at two and four years, % predicted FEV<sub>1</sub> in the 1 mg/kg group changed significantly more than in the placebo group (P &lt; 0.02). During the first two years, the 2 mg/kg group was not significantly different from the placebo group. Linear growth retardation was observed from six months in the 2 mg/kg alternate days prednisolone group and from 24 months in the 1 mg/kg alternate days prednisolone group. </p> <p>Adverse events terminated one four‐year study early. Year 10 follow up showed catch‐up growth started two years after treatment ceased. Alternate‐day treatment with oral corticosteroids may have impaired growth until adulthood in boys. </p> </section> <section id="CD000407-sec-0007"> <h3 class="title" id="CD000407-sec-0007">Authors' conclusions</h3> <p>Oral corticosteroids at prednisolone‐equivalent dose of 1 to 2 mg/kg alternate days appear to slow progression of lung disease in CF; benefit should be weighed against occurrence of adverse events. Risk‐benefit analysis of low‐dose alternate days corticosteroids is important. No further trials of this intervention are anticipated, and hence the review will no longer be regularly updated. However, if any new data are published, these will be incorporate when available. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000407-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000407-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD000407-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD000407-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000407-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD000407-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000407-abs-0002" lang="en"> <h3>Use of oral steroids for cystic fibrosis</h3> <p>Cystic fibrosis causes frequent lung infection and the airways become blocked with mucus. This in turn leads to inflammation, which causes more lung damage and more mucus to be produced. Corticosteroids are strong drugs given to treat this inflammation. The review includes three trials; one for 12 weeks and two with four‐year follow up. We could not combine any data. Trials showed that oral steroids of 1mg/kg to 2 mg/kg (prednisolone equivalent) given every other day seemed to slow the advance of lung disease. However, there are serious adverse effects such as cataracts and the slowing of growth at the higher dose. These led to one trial stopping early. Follow‐up data show that catch‐up growth started two years after treatment ceased. Treatment must use the lowest effective dose and the shortest duration of therapy to reduce the risk of a permanent effect on growth. A dose of 1 mg/kg on alternate days might be considered for up to 24 months, but close attention should be paid to adverse effects. We do not expect any further trials of this treatment to be undertaken, so we do not plan to continue to regularly update the review. However, if any new information is published, we will include this when it is available. This is an update of a previously published review. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000407-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000407-sec-0062"></div> <h3 class="title" id="CD000407-sec-0063">Implications for practice</h3> <section id="CD000407-sec-0063"> <p>Current evidence suggests that oral corticosteroids at a prednisolone equivalent dose of 2 mg/kg on alternate days is effective but should not be used due to the high risk of occurrence of important side effects. A dose of 1 mg/kg on alternate days might be considered for up to 24 months but close attention to the occurrence of adverse effects is warranted. </p> </section> <h3 class="title" id="CD000407-sec-0064">Implications for research</h3> <section id="CD000407-sec-0064"> <p>Although oral corticosteroids at a dose of 1 mg/kg to 2 mg/kg on alternate days appear to slow the progression of lung disease in CF, this is at the expense of the occurrence of adverse events. The evidence from Eigen's study suggests that growth retardation may appear after 24 months of treatment with prednisolone at 1 mg/kg on alternate days and as early as six months with a dose of 2 mg/kg on alternate days (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). Therefore, further RCTs examining the effectiveness and safety of treatment on a long‐term basis are not warranted. However, a survival analysis from the 10‐year follow‐up study (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>) or indeed from the other long‐term study (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>) would be helpful in determining whether the use of oral corticosteroids has any effect on long‐term survival. It would seem prudent to address the effectiveness of alternative anti‐inflammatory agents in future RCTs. </p> <p>We recommend that any future studies should adequately consider adverse effects particularly quality of life measures to assess acceptability to participants. We would urge trialists to recognise that the results of individual RCTs are likely to be included in systematic reviews such as this. They should therefore consider standardising the presentation of outcomes to enable the data to be aggregated. However, despite these recommendations, we do not anticipate any further trials of this intervention, and hence we do not plan to update the review on a regular basis. If we become aware that any new data have been published, we will incorporate these into the review. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000407-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000407-sec-0008"></div> <section id="CD000407-sec-0009"> <h3 class="title" id="CD000407-sec-0009">Description of the condition</h3> <p>The defective cystic fibrosis (CF) gene is responsible for causing an abnormal airway surface environment, which leads to both airway obstruction by mucus plugging and recurrent respiratory infection. This leads to inflammation and eventually long‐term lung damage (bronchiectasis), respiratory failure and death. The persistent presence of pathogenic organisms, including <i>Staphylococcus aureus</i> , <i>Haemophilus influenza</i> , and <i>Pseudomonas aeruginosa</i> in the airways is associated with a powerful inflammatory response which is ineffective in clearing the organisms from the lungs (<a href="./references#CD000407-bbs2-0013" title="Balfour-LynnIM , DinwiddieR . Role of corticosteroids in cystic fibrosis lung disease. Journal of the Royal Society of Medicine1996;89(Suppl 27):8-13.">Balfour‐Lynn 1996</a>). </p> <p>It has been recognised that the inflammatory process itself may contribute to lung injury (<a href="./references#CD000407-bbs2-0021" title="KonstanMW , BergerM . Current understanding of the inflammatory process in cystic fibrosis: onset and etiology [abstract]. In: Proceedings of the 12th International Cystic Fibrosis Conference; 1996 June 16-21; Jerusalem. Jerusalem, 1996.">Konstan 1996</a>). The most characteristic feature of lung inflammation in CF is the influx of huge numbers of white cells, called neutrophils, into the airways (<a href="./references#CD000407-bbs2-0019" title="KonstanMW , BergerM . Cystic Fibrosis. New York: Marcel Dekker Inc, 1993.">Konstan 1993</a>). These numerous neutrophils break down and release a number of substances, including deoxyribonucleic acid (DNA), which makes the sputum thick and sticky. They also release products which cause direct lung damage. These include oxygen metabolites (oxidants) and elastase, which damages the airway wall and increases mucus secretion, therefore aggravating airway obstruction. Elastase also causes the secretion of a substance called IL‐8, a type of cytokine, which attracts more neutrophils into the airways. </p> <p>Bronchoscopy combined with bronchoalveolar lavage (BAL), a technique of examining the airways and getting information about the composition of airway fluids, have helped further understanding of inflammation and lung injury in CF. The inflammatory process occurs early in life, a recent study showing showed that lung inflammation can occur in CF infants as young as four weeks (<a href="./references#CD000407-bbs2-0018" title="KhanTZ , WagenerJS , BostT , MartinezJ , AccursoFJ , RichesDWH . Early pulmonary inflammation in infants with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine1995;151(4):1075-82.">Khan 1995</a>). Another study showed that even infants without clinically obvious lung disease still had evidence of airway infection with inflammation predominated by neutrophils (<a href="./references#CD000407-bbs2-0012" title="ArmstrongDS , GrimwoodK , CarzinoR , CarlinJB , OlinskyA , PhelanPD . Lower respiratory tract infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ1995;310(6994):1570-2.">Armstrong 1995</a>). Studies have also shown that the inflammatory response is also detectable in the airways of people with clinically mild disease (<a href="./references#CD000407-bbs2-0020" title="KonstanMW , HilliardKA , NorvellTM , BergerM . Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild disease suggesting ongoing infection and inflammation. American Journal of Respiratory and Critical Care Medicine1994;150(2):448-54.">Konstan 1994</a>). BAL in people with CF with mild lung disease has been shown to contain large numbers of inflammatory cells, including neutrophils and free elastase (<a href="./references#CD000407-bbs2-0020" title="KonstanMW , HilliardKA , NorvellTM , BergerM . Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild disease suggesting ongoing infection and inflammation. American Journal of Respiratory and Critical Care Medicine1994;150(2):448-54.">Konstan 1994</a>). </p> </section> <section id="CD000407-sec-0010"> <h3 class="title" id="CD000407-sec-0010">How the intervention might work</h3> <p>Current evidence suggests that inflammation in CF occurs early in life and may contribute to lung damage. This is the rationale for the use of anti‐inflammatory therapy in CF. Corticosteroids are powerful anti‐inflammatory agents which have been used widely in a number of diseases for several decades and have several important effects on neutrophils, such as stopping the neutrophils converting to their active state (<a href="./references#CD000407-bbs2-0026" title="SchleimerRP . Effects of glucocorticoids on inflammatory cells relevant to their therapeutic applications in asthma. American Review of Respiratory Disease1990;141:S59-S69.">Schleimer 1990</a>) and stopping them producing digestive enzymes (<a href="./references#CD000407-bbs2-0024" title="Llewellyn-JonesCG , HillSL , StockleyRA . Effect of fluticasone proprionate on neutrophil chemotaxis, superoxide generation, and extracellular proteolytic activity in vitro. Thorax1994;49(3):207-12.">Llewellyn‐Jones 1994</a>). </p> </section> <section id="CD000407-sec-0011"> <h3 class="title" id="CD000407-sec-0011">Why it is important to do this review</h3> <p>This review aims to determine whether there is clear evidence that one anti‐inflammatory treatment, oral corticosteroids, is beneficial in the treatment of lung disease in people with CF. However, the use of corticosteroids is also associated with well‐known, significant side effects. Use of high doses, particularly over a prolonged period of time is associated with changes in appearance including a 'moon‐face', weight gain, centripetal redistribution of fat, muscle wasting, acne, bruising, thinning of the skin and stretch marks. High doses can also precipitate or exacerbate existing diabetes mellitus. Prolonged use is associated with osteoporosis (thinning of the bones) and cataract formation. Corticosteroids also increase the risk of contracting certain types of infection and reduce the capacity of the body to respond to serious infection. In children, one of the most worrying side effects is suppression of growth. </p> <p>This is an update of a previously published review (<a href="./references#CD000407-bbs2-0027" title="ChengK , AshbyD , SmythRL . Oral steroids for cystic fibrosis. Cochrane Database of Systematic Reviews1999, Issue 4. Art. No: CD000407. [DOI: 10.1002/14651858.CD000407]">Cheng 1999</a>; <a href="./references#CD000407-bbs2-0028" title="ChengK , AshbyD , SmythRL . Oral steroids for long-term use in cystic fibrosis. Cochrane Database of Systematic Reviews2011, Issue 10. Art. No: CD000407. [DOI: 10.1002/14651858.CD000407.pub2]">Cheng 2011</a>; <a href="./references#CD000407-bbs2-0029" title="ChengK , AshbyD , SmythRL . Oral steroids for long-term use in cystic fibrosis. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD000407. [DOI: 10.1002/14651858.CD000407.pub3]">Cheng 2013</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000407-sec-0012" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000407-sec-0012"></div> <p>The objective of this review is to determine the effectiveness of oral corticosteroids in the management of CF. We wished to test the hypotheses that oral corticosteroids: </p> <p> <ol id="CD000407-list-0001"> <li> <p>reduce the number of days of intravenous antibiotics for respiratory exacerbations;</p> </li> <li> <p>reduce the need for hospital admission for respiratory exacerbations;</p> </li> <li> <p>improve or prevent the decline in objective tests of lung function (forced expiratory volume in one second (FEV<sub>1</sub>); forced vital capacity (FVC); and forced expiratory flow 25‐75% (FEF<sub>25-75</sub>)); </p> </li> <li> <p>improve exercise tolerance;</p> </li> <li> <p>improve nutritional status;</p> </li> <li> <p>are associated with adverse effects including changes in appearance including Cushingoid appearance, growth suppression, diabetes mellitus, cataracts, osteoporosis and opportunistic infection; </p> </li> <li> <p>improve quality of life;</p> </li> <li> <p>improve survival.</p> </li> </ol> </p> <p>We intended to assess the above hypotheses for long‐term anti‐inflammatory use only.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000407-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000407-sec-0013"></div> <section id="CD000407-sec-0014"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000407-sec-0015"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials, published and unpublished.</p> </section> <section id="CD000407-sec-0016"> <h4 class="title">Types of participants</h4> <p>Children and adults, of any age, with defined CF diagnosed clinically and by sweat or genetic testing. People with CF at all stages of lung disease were included. </p> </section> <section id="CD000407-sec-0017"> <h4 class="title">Types of interventions</h4> <p>Where oral corticosteroids have been compared to placebo or existing conventional therapy for at least 30 days. </p> </section> <section id="CD000407-sec-0018"> <h4 class="title">Types of outcome measures</h4> <section id="CD000407-sec-0019"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD000407-list-0002"> <li> <p>Objective lung function tests</p> <ol id="CD000407-list-0003"> <li> <p>forced expiratory volume at one second (FEV<sub>1</sub>), forced vital capacity (FVC), forced expiratory flow from 25% to 75% of vital capacity (FEF<sub>25-75</sub>) (% predicted) absolute change from baseline </p> </li> <li> <p>FEV<sub>1</sub>, FVC, FEF<sub>25-75</sub> (% predicted) post‐treatment </p> </li> </ol> </li> <li> <p>Number of days of intravenous antibiotics for respiratory exacerbations</p> </li> <li> <p>Hospitalisation rates for respiratory exacerbations</p> </li> </ol> </p> </section> <section id="CD000407-sec-0020"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD000407-list-0004"> <li> <p>Objective change in exercise tolerance as measured by a maximal exercise test, including a 12‐minute walk if this had been measured </p> </li> <li> <p>Change in growth and nutritional indices expressed as change in z scores for height and weight, change in body mass index, percentage weight for height and height and weight centiles. As increase in weight or percentage ideal body weight for height might occur at the expense of reduced growth velocity, we wished to consider these in the context of change in height. Z score is a measure of nutritional status, where weight is expressed as a percentage of ideal for height and then compared to the standard for the population (<a href="./references#CD000407-bbs2-0015" title="FrisanchoAR . Anthropometric standards for the assessment of growth and nutritional status. Ann Arbor: University of Michigan Press, 1990.">Frisancho 1990</a>). </p> </li> <li> <p>Occurrence of adverse effects such as changes in appearance including Cushingoid appearance, growth impairment as measured by change in z score for height, cataracts, osteoporosis, obesity, diabetes mellitus requiring regular treatment, occurrence of opportunistic infection categorised as mild (e.g. oral or vaginal thrush, ringworm) or serious (e.g. shingles, herpes virus, life‐threatening infection). Other adverse effects if noted were also assessed. If data were available, we planned to assess bone mineral density z score as a continuous variable. </p> </li> <li> <p>Quality of life</p> </li> <li> <p>Survival or age at death</p> </li> </ol> </p> </section> </section> </section> <section id="CD000407-sec-0021"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000407-sec-0022"> <h4 class="title">Electronic searches</h4> <p>Relevant studies were identified from the Group's Cystic Fibrosis Trials Register using the terms: anti‐inflammatory AND oral AND steroid. </p> <p>The Cystic Fibrosis Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of <i>The Cochrane Library</i> ), weekly searches of MEDLINE, a search of Embase to 1995 and the prospective handsearching of two journals ‐ <i>Pediatric Pulmonology</i> and the <i>Journal of Cystic Fibrosis</i>. Unpublished work is identified by searching the abstract books of three major cystic fibrosis conferences: the International Cystic Fibrosis Conference; the European Cystic Fibrosis Conference and the North American Cystic Fibrosis Conference. Additional references were found from reference lists. For full details of all searching activities for the register, please see the relevant sections of the <a href="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/CF/frame.html" target="_blank">Cystic Fibrosis and Genetic Disorders Group Module</a>. </p> <p>Date of the most recent search of the Group's Cystic Fibrosis Trials Register: 28 August 2015. </p> </section> <section id="CD000407-sec-0023"> <h4 class="title">Searching other resources</h4> <p>Full text searching of the <i>Journal of Pediatrics</i> was also undertaken from the years 1948 to 1997. </p> </section> </section> <section id="CD000407-sec-0024"> <h3 class="title" id="CD000407-sec-0024">Data collection and analysis</h3> <section id="CD000407-sec-0025"> <h4 class="title">Selection of studies</h4> <p>We (KC and RS) independently applied inclusion criteria to all potential reports.</p> </section> <section id="CD000407-sec-0026"> <h4 class="title">Data extraction and management</h4> <p>We independently attempted to extract data from each randomised controlled trial (RCT) from text, tables and figures. For continuous outcomes, we intended to record either mean absolute change from baseline for each group or mean post‐treatment or intervention values and standard deviation or standard error for each group. </p> <p>We planned to group outcome data into those measured at one, three, six, twelve months and annually thereafter. However, outcome data were recorded at other time periods and reported within this review. For future updates, if outcome data are recorded at other time periods then consideration will be given to examining these as well. </p> </section> <section id="CD000407-sec-0027"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>In order to assess the risk of bias in the included studies, we followed the guidance given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD000407-bbs2-0017" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.">Higgins 2009</a>). We considered such aspects as generation of randomisation sequence and allocation concealment. If we regarded these as adequately performed, then there was a low risk of bias to the study; if we regarded these as inadequately performed, then there was a high risk of bias to the study; and if they were considered unclear then the risk of bias was unclear too. We also considered the degree of blinding and the risk of bias increased as the number of people blinded to the intervention decreased. Finally, we considered whether issues resulting from incomplete outcome data were adequately addressed and whether this led to a low, high or uncertain risk of bias. </p> </section> <section id="CD000407-sec-0028"> <h4 class="title">Measures of treatment effect</h4> <p>We aimed to calculate a pooled estimate of the treatment effect for each outcome across studies. For binary outcomes, we planned to express this as a pooled odds ratio (OR) (the odds of an outcome among treatment allocated participants to the corresponding odds among controls) and for continuous outcomes, we would express a pooled estimate of the treatment effect by calculating the mean difference (MD). </p> <p>The data from these studies are essentially longitudinal in nature. The extractions below are the best that can be hoped for given the constraints of extracting summaries from published reports, although we recognise there are potentially issues of multiple end points. We would require individual patient data for a fuller analysis, but the merits of making the necessary investment are best judged after reviewing the available studies on the basis of reports. </p> </section> <section id="CD000407-sec-0029"> <h4 class="title">Unit of analysis issues</h4> <p>We did not include any cross‐over studies; we do not plan to include any cross‐over studies in the future as we feel these are not appropriate to this intervention. </p> </section> <section id="CD000407-sec-0030"> <h4 class="title">Dealing with missing data</h4> <p>Where sufficient data were not available in the published reports or in the abstract from the conference proceedings, we attempted to contact first and last authors of the studies to obtain individual or summary data. </p> <p>In order to allow an intention‐to‐treat analysis, we planned to collect data on the number of participants with each outcome event, by allocated treated group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up. </p> </section> <section id="CD000407-sec-0031"> <h4 class="title">Assessment of heterogeneity</h4> <p>We intended to test for heterogeneity between study results using a standard chi squared test and the I<sup>2</sup> statistic (<a href="./references#CD000407-bbs2-0016" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60.">Higgins 2003</a>). We planned to grade the degrees of heterogeneity using the I<sup>2</sup> values as follows: low (0% to 40%), moderate (30% to 60%), substantial (50% to 90%) and considerable (75% to 100%). </p> </section> <section id="CD000407-sec-0032"> <h4 class="title">Data synthesis</h4> <p>We have analysed the data using a fixed‐effect model. If, in future updates of this review, we identify substantial or considerable heterogeneity, we will consider analysing the data using a random‐effects model. </p> </section> <section id="CD000407-sec-0033"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>For future updates, if there are sufficient numbers of studies we will explore the following sources of heterogeneity: </p> <p> <ol id="CD000407-list-0005"> <li> <p>age of participants;</p> </li> <li> <p>interaction with other drugs.</p> </li> </ol> </p> </section> <section id="CD000407-sec-0034"> <h4 class="title">Sensitivity analysis</h4> <p>We will also examine the robustness of our results using a sensitivity analysis including and excluding studies with a high risk of bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000407-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000407-sec-0035"></div> <section id="CD000407-sec-0036"> <h3 class="title">Description of studies</h3> <section id="CD000407-sec-0037"> <h4 class="title">Results of the search</h4> <p>Eleven studies were identified by the searches. Three studies met the inclusion criteria (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>; <a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>; <a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>); four studies were excluded (<a href="./references#CD000407-bbs2-0004" title="Cohen-CymberknohM , BlauH , ShoseyovD , EfratiO , ArmoniS , KeremE . Intravenous methylprednisolone pulse therapy vs. oral prednisone for allergic bronchopulmonary aspergillosis (ABPA) in CF [abstract]. Journal of Cystic Fibrosis2008;7(Suppl 2):S58. [CFGD REGISTER: PI219a] 5500100000003257 Cohen-CymberknohM , BlauH , ShoseyovD , Mei-ZahavM , EfratiO , ArmoniS , et al. Intravenous monthly high-dose pulse methylprednisolone vs oral prednisone for therapy of allergic bronchopulmonary aspergillosis in cystic fibrosis [abstract]. American Journal of Respiratory and Critical Care Medicine2009;179 Suppl:Abstract no: A1184. [CFGD REGISTER: PI219b] 5500100000010588 ">Cohen‐Cymberknoh 2008</a>; <a href="./references#CD000407-bbs2-0005" title="DoveyM , AitkenML , EmersonJ , McNamaraS , DormanD , GibsonRL . A randomised, double-blind, placebo-controlled trial of oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbations [abstract]. Pediatric Pulmonology2004;38 (Suppl 27):301. DoveyM , AitkenML , EmersonJ , McNamaraS , WaltzDA , GibsonRL . Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest2007;132(4):1212-8. ">Dovey 2007</a>; <a href="./references#CD000407-bbs2-0006" title="LinnaneSJ , ThinAG , KeatingsVM , MoynihanJB , McLoughlinP , FitzGeraldMX . Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients. European Respiratory Journal2001;17(6):1267-70. ">Linnane 2001</a>; <a href="./references#CD000407-bbs2-0007" title="PantinCFA , SteadRJ , HodsonME , BattenJC . Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. Thorax1986;41(1):34-8. SteadRJ , PantinCFA , HodsonME , BattenJC . Prednisolone in the treatment of airflow obstruction [abstract]. In: Proceedings of the 13th Annual Meeting of the European Working Group for Cystic Fibrosis; 1985 November 3-8; Jerusalem, Israel. 1985:112. ">Pantin 1986</a>); and four studies are listed as awaiting classification (we do not currently have sufficient details to assess whether these studies are eligible for inclusion in our review and have contacted the authors of the study for more information) (<a href="./references#CD000407-bbs2-0008" title="KapustinaT , FedorovaV , VoronkovaA , KapranovN . Long-term treatment with corticosteroids and bone mineral density in patients with cystic fibrosis [abstract]. In: European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany. 2008:214s. ">Kapustina 2008</a>; <a href="./references#CD000407-bbs2-0009" title="NyamugunduruG , DesaiM , RaynerRJ , SimmondsE , WellerP , SpencerDA . A double blind parallel placebo-controlled randomised study of oral prednisolone in acute respiratory exacerbations in children with cystic fibrosis. Thorax1998;53(Suppl 4):A61. NyamugunduruG , DesaiM , SpencerD , ClarkeJ , WellerP . A double blind parallel placebo-controlled randomised study of the addition of short-course oral prednisolone in treatment of acute respiratory exacerbations in children with cystic fibrosis [abstract]. In: Proceedings of 22nd European Cystic Fibrosis Conference, 1998 June 13-18; Berlin. 1998:79. NyamugunduruG , DesaiM , WellerP , SpencerDA . The effect of oral prednisolone on serum interleukin-8 concentrations in acute respiratory exacerbations in children with cystic fibrosis [abstract]. In: Proceedings of 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm. Stockholm, 2000:183. ">Nyamugunduru 1998</a>; <a href="./references#CD000407-bbs2-0010" title="PukhalskyA , ShmarinaG , PukhalskayaD , PerederkoL , KashirskayaN , KapranovN . Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients? [abstract]. In: Proceedings of European Respiratory Society Annual Congress; 2007 Sep 15-19; Stockholm, Sweden. 2007:31s, Abstract no: E345. [CFGD REGISTER: IB96] 5500100000010731 ">Pukhalsky 2007</a>; <a href="./references#CD000407-bbs2-0011" title="PukhalskyA , ShmarinaG , PukhalskayaD , PerederkoL . Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment? [abstract]. In: European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany. 2008:216s. ">Pukhalsky 2008</a>). </p> </section> <section id="CD000407-sec-0038"> <h4 class="title">Included studies</h4> <p>Summary details are given in the <a href="./references#CD000407-sec-0075" title="">Characteristics of included studies</a> tables, including the time points reported in the primary studies. </p> <p>Seven studies were identified by the searches, of which three, with a total of 354 participants, met the inclusion criteria. </p> <section id="CD000407-sec-0039"> <h5 class="title">Participants</h5> <p>The ages of the participants ranged from 1 year to 19.5 years. In one study, the participants were stated as having mild to moderate lung disease, but an objective measure of lung disease, such as mean per cent predicted FEV<sub>1</sub>, was not reported (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). In the other two studies the upper or lower limits of severity of lung disease were stated as FEV<sub>1</sub> less than 85% predicted in one (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>); and as FEV<sub>1</sub> greater than 60% predicted in the other (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). </p> </section> <section id="CD000407-sec-0040"> <h5 class="title">Interventions</h5> <p>Two studies examined alternate‐day corticosteroids (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>; <a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>), in the third study corticosteroids were given daily for the first two weeks and then on alternate days for 10 weeks (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). In each study the comparison of treatment was with placebo and in one study two doses were compared with placebo (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). The dose of prednisolone varied from 1mg/kg day on alternate days (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>) to 2 mg/kg on alternate days (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>; <a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>) to 2 mg/kg daily for 14 days followed by 1 mg/kg on alternate days for 10 weeks (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>).<br/><br/>The duration of administration of oral corticosteroids and follow up ranged from 12 weeks (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>) to four years (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>; <a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). Although not strictly a 'short‐term' study (less than 30 days), the study by Greally was a short‐term one in comparison to the other two studies (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). It was also primarily explanatory rather than pragmatic; its aim was to explore the biological mechanisms of oral corticosteroids, rather than to give treatment recommendations (<a href="./references#CD000407-bbs2-0025" title="MurrayGD . Statistical aspects of research methodology. British Journal of Surgery1991;78(7):777-81.">Murray 1991</a>). The authors had previously demonstrated higher serum concentration of interleukin‐1alpha and interleukin‐2R in participants with CF compared to controls; and in this study aimed to investigate the effect of oral prednisolone on these interleukins and also immunoglobulin G (IgG). In one of the long‐term studies no intermediate outcome data were presented between baseline and four years (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). </p> </section> <section id="CD000407-sec-0041"> <h5 class="title">Outcome measures</h5> <p>Four outcomes, which we had intended to assess, had not been reported in any of the three RCTs. These were exercise tolerance, number of days of intravenous antibiotics for respiratory exacerbations, quality of life and survival. The two outcomes common to all three studies were lung function and adverse events. </p> <p>However, data on the lung function primary endpoint were presented in different ways in each study. In the study by Greally, lung function was expressed as mean absolute change in per cent predicted FEV<sub>1</sub> at 14 days and 12 weeks, with confidence levels for the change quoted (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). In the Auerbach study the mean absolute level of per cent predicted FEV<sub>1</sub> at baseline and four years were reported, together with standard error (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). In the third study graphs of mean change from baseline of FEV<sub>1</sub> and FVC were shown but no standard errors or standard deviations were reported (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). </p> <p>The adverse events reported were not the same in each study. The Greally study specifically sought the adverse events of raised blood pressure, high blood sodium, low blood potassium, fluid retention and blood glucose abnormalities (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). The Auerbach study regularly measured height and weight of participants, but other adverse effects did not seem to have been systematically sought (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). The Eigen study monitored adverse events at each clinic visit, i.e. three‐monthly, specifically looking for raised blood glucose levels, cataracts, liver enzyme abnormalities, or chest infections with unusual organisms (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). In the <a href="#CD000407-sec-0047">Effects of interventions</a> section of this review, the adverse events are described as they have been reported in the published reports. None of the studies reported whether or not Cushingoid appearance or osteoporosis had developed. Two of the three studies reported effect on height (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>; <a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>); although, as the other study was comparatively short, there would not have been sufficient time for an effect on height to have occurred (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). Two of the three studies reported the development of diabetes or glucose intolerance (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>; <a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). Two studies evaluating different groups of participants reported the development of cataracts; one was a four‐year follow‐up study (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>) and the other a 10‐year follow up of some of the participants in another four‐year study (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). Only one study reported the development of opportunistic infection (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). </p> <p>In the study by Eigen, due to an excess of adverse events, the high dose prednisolone (2 mg/kg on alternate days) group was discontinued prematurely three years after accrual of participants commenced and the low dose (1mg/kg on alternate days) was also discontinued a year later (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). All three treatment groups were analysed using a repeated measures ANOVA for the first 24 months, but a second analysis was done comparing the 1 mg/kg prednisolone group with placebo for 48 months. Participants, who were in the 2 mg/kg on alternate days group, were not included in the latter analysis because some participants in this group had not received the study drug for as long as 24 months. For either treatment group it was not clear from the report exactly how long oral corticosteroids were given, but it appears to have been a variable length of time, depending on when enrolment into the study took place. </p> </section> </section> <section id="CD000407-sec-0042"> <h4 class="title">Excluded studies</h4> <p>Four studies were excluded from the review: one study was not randomised (<a href="./references#CD000407-bbs2-0007" title="PantinCFA , SteadRJ , HodsonME , BattenJC . Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. Thorax1986;41(1):34-8. SteadRJ , PantinCFA , HodsonME , BattenJC . Prednisolone in the treatment of airflow obstruction [abstract]. In: Proceedings of the 13th Annual Meeting of the European Working Group for Cystic Fibrosis; 1985 November 3-8; Jerusalem, Israel. 1985:112. ">Pantin 1986</a>) and another study did not meet our inclusion criteria as the steroids were not given to treat an exacerbation (<a href="./references#CD000407-bbs2-0006" title="LinnaneSJ , ThinAG , KeatingsVM , MoynihanJB , McLoughlinP , FitzGeraldMX . Glucocorticoid treatment reduces exhaled nitric oxide in cystic fibrosis patients. European Respiratory Journal2001;17(6):1267-70. ">Linnane 2001</a>). The third study was excluded as treatment duration was less than 30 days (<a href="./references#CD000407-bbs2-0005" title="DoveyM , AitkenML , EmersonJ , McNamaraS , DormanD , GibsonRL . A randomised, double-blind, placebo-controlled trial of oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbations [abstract]. Pediatric Pulmonology2004;38 (Suppl 27):301. DoveyM , AitkenML , EmersonJ , McNamaraS , WaltzDA , GibsonRL . Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest2007;132(4):1212-8. ">Dovey 2007</a>) and the remaining study was excluded as the steroids were given to treat allergic bronchopulmonary aspergillosis and not as part of the general anti‐inflammatory management of CF (<a href="./references#CD000407-bbs2-0004" title="Cohen-CymberknohM , BlauH , ShoseyovD , EfratiO , ArmoniS , KeremE . Intravenous methylprednisolone pulse therapy vs. oral prednisone for allergic bronchopulmonary aspergillosis (ABPA) in CF [abstract]. Journal of Cystic Fibrosis2008;7(Suppl 2):S58. [CFGD REGISTER: PI219a] 5500100000003257 Cohen-CymberknohM , BlauH , ShoseyovD , Mei-ZahavM , EfratiO , ArmoniS , et al. Intravenous monthly high-dose pulse methylprednisolone vs oral prednisone for therapy of allergic bronchopulmonary aspergillosis in cystic fibrosis [abstract]. American Journal of Respiratory and Critical Care Medicine2009;179 Suppl:Abstract no: A1184. [CFGD REGISTER: PI219b] 5500100000010588 ">Cohen‐Cymberknoh 2008</a>). </p> </section> </section> <section id="CD000407-sec-0043"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD000407-sec-0044"> <h4 class="title">Allocation</h4> <p>Generation of the randomisation sequence, and also the risk of bias due to this, was unclear in two studies (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>; <a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). We judged the generation of randomisation sequence to be adequate and estimated the risk of bias from this as low in the third study, which used a computer‐generated random number sequence in blocks of six (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). </p> <p>Concealment of allocation was unclear in all three included studies and we deemed these to have an unclear risk of bias (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>; <a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>; <a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). </p> </section> <section id="CD000407-sec-0045"> <h4 class="title">Blinding</h4> <p>Double blinding was reported specifically in all three studies (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>; <a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>; <a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). However, the authors acknowledge that double‐blinding might not have been possible. At the doses used, it would have been obvious from the somatic changes resulting from the use of corticosteroids, which participants were in the treatment group. We therefore judged all three studies to have an unclear risk of bias due to blinding (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>; <a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>; <a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). </p> </section> <section id="CD000407-sec-0046"> <h4 class="title">Incomplete outcome data</h4> <p>Analysis was done on an intention‐to‐treat basis in two studies and this led us to estimate a low risk of bias for these studies (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>; <a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). In the third study, 45 participants were initially randomised, but 11 did not complete the study (reasons were given) (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). It was unclear whether these 11 withdrawals had been included in the analysis. We therefore judged this study to have an unclear risk of bias (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). </p> </section> </section> <section id="CD000407-sec-0047"> <h3 class="title" id="CD000407-sec-0047">Effects of interventions</h3> <p>Due to the variations in presentation of data and the different time points at which outcomes were examined, no aggregation of data was possible. We have been unsuccessful so far in obtaining raw data from two of the studies; however, we have received the data from the remaining study (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). We have not been able to contact any of the authors of the study by Auerbach (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>), but have been assured by the authors of the study by Eigen that they will send us their raw data (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). For this review we have summarised the data as presented in the published reports. Hence we currently report P values, rather than actual group data, with the results of each outcome as a mean for each group or percentages together with confidence intervals (CIs). However, with the exception of the study by Greally, this has not been possible because the data were not expressed in this way in the published reports (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). The authors acknowledge that the reader will have difficulty in assessing whether a statistically significant change is also clinically important. </p> <section id="CD000407-sec-0048"> <h4 class="title">Primary outcomes</h4> <section id="CD000407-sec-0049"> <h5 class="title">1. Objective lung function tests</h5> <p>All studies showed some improvement or delay in decline in lung function in the oral steroid‐treated groups compared with placebo. </p> <section id="CD000407-sec-0050"> <h6 class="title">a. FEV<sub>1</sub>/FVC/FEF<sub>25-75</sub> (% predicted) absolute change from baseline </h6> <p>Greally examined lung function at relatively short time points, 14 days and 12 weeks (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). Mean absolute change in percent predicted FEV<sub>1</sub> with the 95% CI for the difference between groups were reported at 14 days and 12 weeks. The mean absolute change in percent predicted FEV<sub>1</sub> at 14 days was 7.7% in the treatment group compared to ‐1.0% in the placebo group (95% CI for the difference between groups 15.08 to 2.32) and at 12 weeks was 6.3% in the prednisolone group compared to ‐1.8% in the placebo group (95% CI 15.75 to 0.45). The improvement observed in the treatment group is likely to be perceived as beneficial by the participant. We assumed that the standard deviation for both treatment and control groups was the same and, using the formulae for calculating the standard error of the difference between two means and the confidence interval of the difference between two means, calculated the standard deviations of the two groups. Data on FEV<sub>1</sub> and FVC have been entered into the data tables. </p> <p>Auerbach reported that at four years the mean per cent predicted FEV<sub>1</sub> was significantly higher in the prednisolone group at a dose of 2 mg/kg on alternate days (103%) compared to the placebo group (87%), P &lt; 0.005. At baseline both groups had similar mean per cent predicted FEV<sub>1</sub> (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). </p> <p>In the study by Eigen, an excess of adverse events resulted in the high dose prednisolone (2 mg/kg on alternate days) being discontinued prematurely three years after accrual of participants commenced and the low dose was also discontinued a year later (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). All three treatment groups were analysed using a repeated measures ANOVA for the first 24 months but a second analysis was done comparing the 1 mg/kg on alternate days prednisolone group with placebo for 48 months. Actual group data were not reported. </p> <p>Actual group data for FEV<sub>1</sub> and FVC were not reported. With regards to FVC, when the three groups were compared for the initial 24 months, the mean change in per cent predicted FVC was higher in the 1 mg/kg group than the placebo group at all six‐monthly time points (P &lt; 0.0001); and at all time points the mean change in per cent predicted FVC was greater in the 2 mg/kg group than the placebo group (P &lt; 0.01). When the 1 mg/kg prednisolone group and the placebo group were compared for the first 48 months of the study, the steroid treated group had a greater change in per cent predicted FVC, which was sustained throughout the period (P &lt; 0.0025). At 24 months, 70.4% participants treated with 1 mg/kg prednisolone had an increase in per cent predicted FVC, compared with 54.9% participants treated with 2 mg/kg prednisolone and 41.6% participants treated with placebo. With regards to FEV<sub>1</sub>, during the first 24 months, the 1 mg/kg prednisolone group had a significantly greater change from baseline in per cent predicted FEV<sub>1</sub> than placebo. There was no significant difference between the 2 mg/kg group and the placebo group. When the 1 mg/kg prednisolone group were compared for the full 48 months of the study, the prednisolone treated group had a better change from baseline in mean per cent predicted FEV<sub>1</sub> than the placebo group (P &lt; 0.02), in that there was a decline in mean per cent predicted FEV<sub>1</sub> in the placebo group from 79.2% at baseline to 73.4% at 48%, but no decline in the prednisolone treated group. </p> </section> </section> <section id="CD000407-sec-0051"> <h5 class="title">2. Number of days of intravenous antibiotics for respiratory exacerbations</h5> <p>This outcome was not reported in any of the four studies.</p> </section> <section id="CD000407-sec-0052"> <h5 class="title">3. Hospitalisation rates for respiratory exacerbations</h5> <p>Eigen reported that the hospitalisation rates were similar in the three comparison groups: 52% in the 1 mg/kg group; 59% in the 2 mg/kg group; and 59% in the placebo group (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). It was also noted that hospitalisations per participant were similar in the three groups: 1.73 in the 1 mg/kg group; 1.82 in the 2 mg/ kg group; and 1.86 in the placebo group. The periods during which these hospitalisations per participant were calculated is not clear from the report. </p> <p>Auerbach reported that five (24%) of the prednisolone‐treated participants were admitted to hospital nine times during 846 patient‐months at risk and 10 (42%) placebo‐treated participants were admitted 35 times during 941 patient‐months at risk (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). </p> <p>Greally did not report hospital admissions (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). </p> </section> </section> <section id="CD000407-sec-0053"> <h4 class="title">Secondary outcomes</h4> <section id="CD000407-sec-0054"> <h5 class="title">1. Exercise tolerance</h5> <p>None of the four studies reported this outcome.</p> </section> <section id="CD000407-sec-0055"> <h5 class="title">2. Growth and nutrition</h5> <section id="CD000407-sec-0056"> <h6 class="title">Height</h6> <p>Height was reported in two studies but presented differently, as mean height and weight in one study (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>) and as height z scores in the other (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). </p> <p>Auerbach demonstrated that the mean height of the prednisolone group, (2 mg/kg on alternate days) was higher at four years than the placebo group (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). In the publication the P value was stated as P &lt; 0.025, but the actual changes in each group were not reported. However, long‐term follow‐up data of this study did suggest an adverse effect on linear growth. In the Auerbach study, Donati suggested in the 10‐year follow‐up data of 30 out of the 34 participants that there was substantial impairment in growth in the participants who received corticosteroids for four years or more (<a href="./references#CD000407-bbs2-0014" title="DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;Suppl 5:322.">Donati 1990</a>). Of the 14 participants who were in the original steroid group, nine took corticosteroids for an average (SD) of 9.5 years (1.2 years) and had a mean z score at 10 years of ‐1.86 (95% CI ‐2.44 to ‐1.28), and the five who stopped taking corticosteroids for 4.5 years (0.46 years) had a mean z score of ‐1.34 (95% CI ‐2.58 to ‐0.10). In contrast, of the 16 participants in the placebo group, five never received corticosteroids and five received corticosteroids for 0.6 years (0.3 years) and had a mean z score of ‐0.70 (95% CI ‐1.3 to ‐0.10). The figures for the means and standard deviations were reported in the original paper (<i>see</i><a href="#CD000407-tbl-0001">Table 1</a>), the 95% CIs have been calculated from these figures. The authors of this review acknowledge that this was an incomplete follow‐up study and that although one of the 30 participants died; we do not know why data on the other three were unavailable. </p> <div class="table" id="CD000407-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Long‐term growth ‐ follow up data at 4 years (Auerbach 1985)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Time</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Group I</b> </p> <p><b>n = 9</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Group II</b> </p> <p><b>n = 5</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Group III</b> </p> <p><b>n = 10</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Group IV</b> </p> <p><b>n = 6</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study (4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow up (10 yrs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Group I: originally randomised to steroids for 4 years, continued on steroids for mean (SD) 9.5 (1.2) years<br/>Group II: originally randomised to steroids for 4 years, ceased taking steroids after mean (SD) 4.5 (0.46) years<br/>Group III: originally randomised to placebo for 4 years, 5 in this group never received steroids and 5 received variable doses of steroids for mean (SD) 0.6 (0.3) years<br/>Group IV: originally randomised to placebo for 4 years, subsequently received steroids for mean (SD) 3.6 (1.2) years<br/>SD: standard deviation </p> </div> </div> <p>Eigen also showed that treatment with prednisolone adversely affected growth (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). Evidence of this was apparent six months from starting the study in the 2 mg/kg prednisolone group, but not until 24 months in the 1 mg/kg prednisolone group. Linear growth retardation, as defined in this study by a decrease of one z score, occurred statistically significantly more often in the steroid‐treated participants at either dose, than those treated with placebo (P &lt; 0.05) in the 1 mg prednisone group OR 2.58 (95% CI 1.18 to 5.63); and for the 2 mg prednisone group OR 3.70 (95% CI 1.73 to 7.92) (<a href="./references#CD000407-fig-0003" title="">Analysis 1.3</a>). </p> <p>Following six months of treatment and after 12, 18 and 24 months, the high‐dose group had a significantly greater reduction in height z score than the placebo‐treated group (P &lt; 0.001). For the 1 mg/kg group the height z score was significantly lower than that of the placebo group after 24 months of treatment and also at 36 and 48 months (P &lt; 0.001). Confidence intervals or standard errors were not reported. At 24 months the mean change in height z score was 0.02% for the placebo group, ‐0.1% for the 1 mg/kg prednisolone group and ‐0.3% for the 2 mg/kg prednisolone group; at 36 months ‐0.01% for the placebo group, ‐0.25% for the 1 mg/kg group; and at 48 months ‐0.05% for the placebo group and ‐0.5% for the 1 mg/kg group. These values were read off a graph in the published report. </p> <p>Lai evaluated long‐term growth in 224 of the 243 children enrolled in the Eigen study (<a href="./references#CD000407-bbs2-0022" title="LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;Suppl 19:297.">Lai 1999</a>). Growth patterns were examined six to seven years after prednisolone was discontinued. At this stage (in 1997) 68% of the participants were 18 years or older. Height z scores among prednisolone‐treated participants declined from baseline to three to four years in both genders. Catch‐up growth began two years after prednisolone was discontinued. </p> <p>Among the boys, the z scores for height remained significantly lower after 10 years in those who received prednisolone than in those who received placebo (P = 0. 03). The mean height for boys aged 18 years or older was significantly lower (by 13 percentile points) in the boys who received low‐dose prednisolone (P = 0.03); in the 1mg prednisone group, MD ‐3.90 (95% CI ‐7.77 to ‐0.03) and the 2mg prednisone group, MD ‐4.10 (95% CI ‐7.82 to ‐0.38) (<a href="./references#CD000407-fig-0004" title="">Analysis 1.4</a>). The impact of growth suppression was more pronounced and final adult height was affected if the prednisolone was started before puberty. In girls there was no significant difference in height after 18 years of age in those who received prednisolone compared to those who received placebo (P = 0.87); in the 1 mg prednisone group MD ‐1.00 (95% CI ‐4.54 to 2.54) and for the 2 mg prednisone group MD ‐0.50 (95% CI ‐4.43 to 3.43) (<a href="./references#CD000407-fig-0005" title="">Analysis 1.5</a>). Among the girls, no significant differences in z scores for height were found among prednisolone groups after six years (P = 0.26). In addition, girls who started taking prednisolone at younger ages did not have greater declines in z scores for height than girls who started at older ages. In the follow up of the Eigen study, Lai did not state whether formal tests of interaction were undertaken (<a href="./references#CD000407-bbs2-0022" title="LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;Suppl 19:297.">Lai 1999</a>). </p> </section> <section id="CD000407-sec-0057"> <h6 class="title">Weight</h6> <p>All three studies presented data on weight (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>; <a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>; <a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). However, only data from two studies could be entered in the analysis; one study presented data for change in weight (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>) and the remaining study presented weight in kg (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). </p> <p>Auerbach demonstrated that the mean height and weight of the prednisolone group, (2 mg/kg on alternate days) was higher at four years than the placebo group (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). In the publication the P values were stated as P &lt; 0.025 for height and P &lt; 0.005 for weight, but the actual changes in each group were not reported. </p> <p>Greally reported the change in weight from baseline; weight gain was higher in the oral steroid group, but the result was not significant, MD 0.34 (95% CI ‐2.32 to 3.00) (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>) (<a href="./references#CD000407-fig-0006" title="">Analysis 1.6</a>). </p> <p>Eigen presented absolute values for weight at over 18 years of age split for males and females. For the boys, weight was higher in both treatment groups compared to placebo; this was not statistically significant in the 1mg prednisone group MD ‐4.60 (95% CI ‐9.69 to 0.49), but was statistically significant in the 2 mg prednisone group MD ‐6.70 (95 % CI ‐11.59 to ‐1.81]) (<a href="./references#CD000407-fig-0007" title="">Analysis 1.7</a>). For the girls, weight was higher in the 1 mg prednisone group compared to placebo, MD ‐2.30 (95% CI ‐6.74 to 2.14); but lower in the 2 mg prednisone group compared to placebo, MD 1.70 (95% CI ‐3.37 to 6.77) (<a href="./references#CD000407-fig-0008" title="">Analysis 1.8</a>). Neither result was statistically significant for the girls. </p> <p>Obesity was not reported in any of the studies.</p> </section> </section> <section id="CD000407-sec-0058"> <h5 class="title">3. Occurrence of adverse effects</h5> <p>(e.g. changes in appearance including Cushingoid appearance, cataracts, osteoporosis, obesity, diabetes mellitus requiring regular treatment, occurrence of opportunistic infection categorised as mild (e.g. oral or vaginal thrush, ringworm) or serious (e.g. shingles, herpes virus, life‐threatening infection)) </p> <p>We described earlier which of these adverse events were systematically sought during the course of the studies and have described the occurrence of these outcomes as they were reported in the published reports. As stated in the '<a href="#CD000407-sec-0036">Description of studies</a>' section, 95% CIs were not reported. The study by Auerbach was not analysed on an 'intention‐to‐treat' basis and there was further loss to follow up at 10 years (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). Therefore, it was not possible to calculate percentages or rates for any adverse effects. Eigen reported adverse events, but it is not possible to differentiate whether more than one event occurred in the same participant, so again it is not possible to report percentages or rates (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). </p> <p>The development of a Cushingoid appearance was reported in one study and occurred in four of the prednisolone‐treated participants (2 mg/kg on alternate days) (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). </p> <p>Development of cataracts was reported in two studies. The 10‐year follow‐up report of the Auerbach study by Donati reported that two participants had developed cataracts (<a href="./references#CD000407-bbs2-0014" title="DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;Suppl 5:322.">Donati 1990</a>). Eigen reported that during the first 24 months, cataracts were seen more often in participants in the 2 mg/kg prednisolone group (11 participants) compared to the 1 mg/kg group (three participants) (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). We also noted that seven participants in the placebo group developed cataracts. </p> <p>Osteoporosis was not specifically noted, but in the follow up to the Auerbach study, Donati reported that two of the prednisolone‐treated participants (2mg/kg on alternate days) developed multiple bone fractures (<a href="./references#CD000407-bbs2-0014" title="DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;Suppl 5:322.">Donati 1990</a>). </p> <p>Diabetes mellitus requiring regular treatment was not specifically reported in any of the four studies but all four noted varying degrees of glucose intolerance. In the short‐term study, Greally reported that one participant developed hyperglycaemia (17 mmol/L) at the end of two weeks of 2 mg/kg prednisolone which settled on the alternate‐day regimen (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). In the follow up to the Auerbach study, Donati reported that glucose intolerance occurred in 2 of the 14 prednisolone‐treated participants (2 mg/kg on alternate days) in whom data were available (<a href="./references#CD000407-bbs2-0014" title="DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;Suppl 5:322.">Donati 1990</a>). Eigen noted that abnormalities in glucose metabolism (elevated haemoglobin A1c, raised fasting blood glucose concentration or glucose in the urine) were seen more often in the prednisolone 2 mg/kg group than in the 1 mg/kg group (P &lt; 0.05) but there was no difference between the 1 mg/kg and placebo groups (P &lt; 0.05) (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). </p> <p>Interestingly, occurrence of opportunistic infection was reported only in the shorter‐term study (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). No opportunistic infections occurred in the treated group but it was not reported whether any occurred in the control group. </p> </section> <section id="CD000407-sec-0059"> <h5 class="title">4. Quality of life</h5> <p>This was not specifically reported in any of the three studies.</p> </section> <section id="CD000407-sec-0060"> <h5 class="title">5. Survival or age at death</h5> <p>This was not reported in any of the three studies.</p> <p>Although not a specific outcome, Auerbach reported that during four years of the study, one participant from the placebo group and none from the prednisolone group died (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000407-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000407-sec-0061"></div> <p>Oral corticosteroids at a dose of 1 mg/kg to 2 mg/kg (prednisolone equivalent) administered on alternate days over 12 weeks to 4 years appeared to slow the progression of lung disease in CF as supported by FEV<sub>1</sub> and FVC values documented longitudinally. However, in the long term this benefit needs to be weighed against the occurrence of adverse effects (glucose abnormalities, cataracts and growth retardation), especially linear growth suppression. At the higher dose of 2 mg/kg on alternate days, the occurrence of adverse events resulted in early termination of one study by a data safety monitoring committee, outweighing any beneficial effects on lung function (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). The number of days participants had been taking the dose of 2 mg/kg on alternate days was not stated in the published report. Accrual of participants took place between April 1986 and December 1987. Termination of the high dose was in August 1990. Although adverse events were not reported in the other study which used this dose, this may be due to the smaller sample size used (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). It was disappointing that the contrasting results of the two studies using the higher dose, 2 mg/kg on alternate days, could not be aggregated because of differing presentation of data and the lack of any interim data between baseline and four years in one of these studies. We have attempted unsuccessfully to obtain the raw data from these two studies. Even at the lower dose of 1 mg/kg on alternate days, recommendations to terminate the study prematurely were made, due to the occurrence of adverse effects (glucose abnormalities, cataracts and growth retardation) (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). Long‐term follow up of the Eigen study has shown that the height deficit in boys persisted six to seven years after discontinuation of prolonged alternate‐day treatment with prednisolone (<a href="./references#CD000407-bbs2-0023" title="LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9.">Lai 2000</a>). It is likely that the shorter adult height was due partly to the effect of long‐term treatment with prednisolone and not just the underlying CF. This difference was not seen in girls. These long‐term data suggest that when oral corticosteroids are used in people with CF, treatment regimens need to be adjusted to find the lowest effective dose and the shortest duration of therapy in order to minimise the risk of permanent growth impairment, especially in boys. It is very important that the benefits in improved lung function are weighed against the risk to long‐term growth. </p> <p>Although the shorter‐term study was primarily explanatory, examining the biological effects of corticosteroids on inflammatory markers, lung function was also assessed and showed an improvement in FEV<sub>1</sub> at both 14 days and 12 weeks, but in this relatively short time period no adverse effects occurred (<a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). </p> <p>It is disappointing that effects on survival and quality of life measures were not assessed. The development of Cushingoid appearance was reported in only one study (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>). This is a particularly important outcome to people with CF as the resulting effect on quality of life might not compensate for any improvement in breathlessness. </p> <p>Although we have not been able to perform a formal meta‐analysis for any outcome at any time‐point, this review has summarised the best information currently available. It is important to note that of the three studies included in this review only one was assessed to be of good quality (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>). Information to fully assess the quality of the other two studies was not available (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>; <a href="./references#CD000407-bbs2-0003" title="GreallyP , HussainPJ , VerganiD , PriceJF . Interleukin-1alpha, soluble interleukin-2 receptor, and IgG concentrations in cystic fibrosis treated with prednisolone. Archives of Disease in Childhood1994;71(1):35-9. GreallyP , SampsonAJ , PiperPJ , PriceJF . Effect of prednisolone on airways obstruction in patients with cystic fibrosis [abstract]. European Respiratory Journal1992;5(Suppl 15):259s. GreallyP , SampsonAP , PiperAJ , PriceJF . Prednisolone reduces airways obstruction in children with cystic fibrosis [abstract]. In: Proceedings of the 11th International Cystic Fibrosis Conference; 1992; Dublin, Ireland. 1992:TS12. ">Greally 1994</a>). We have been unable to contact any of the authors of the Auerbach study (<a href="./references#CD000407-bbs2-0001" title="AuerbachHS , WilliamsM , KirkpatrickJA , ColtenHR . Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet1985;2(8457):686-8. DonatiMA , HaverK , GersonW , KleinM , McLaughlinFJ , WohlMEB . Long-term alternate day prednisone therapy in cystic fibrosis [abstract]. Pediatric Pulmonology1990;9 (Suppl 5):322. ">Auerbach 1985</a>), but we have been assured that the data from the Eigen study (<a href="./references#CD000407-bbs2-0002" title="EigenH , RosensteinBJ , FitzsimmonsS , SchidlowDV , and The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Journal of Pediatrics1995;126(4):515-23. HsuJ , KuhnsLR . Longitudinal study in bone absorptiometry in children with cystic fibrosis enrolled in steroid study [abstract]. Pediatric Pulmonology1991;Suppl 6:324. LaiHC , FitzSimmonsSC , AllenDB , KosorokMR , RosensteinBJ , CampbellPW , et al. Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. New England Journal of Medicine2000;342(12):851-9. LaiHC , KosorokMR , AllenDB , FitzSimmonsSC , RosensteinBJ , CampbellPW , et al. Long-term growth evaluation in children with cystic fibrosis with history of regular use of alternate-day prednisone therapy [abstract]. Pediatric Pulmonology1999;28 (Suppl 19):297. RosensteinBJ , EigenH . Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics1991;87(2):245-6. ">Eigen 1995</a>), currently on a data tape will be sent to us in due course. We hope to include a quantitative analysis in a future update of this review. </p> <p>We have identified three abstracts presented at conferences relating to the same RCT by Nyamugunduru (<a href="./references#CD000407-bbs2-0009" title="NyamugunduruG , DesaiM , RaynerRJ , SimmondsE , WellerP , SpencerDA . A double blind parallel placebo-controlled randomised study of oral prednisolone in acute respiratory exacerbations in children with cystic fibrosis. Thorax1998;53(Suppl 4):A61. NyamugunduruG , DesaiM , SpencerD , ClarkeJ , WellerP . A double blind parallel placebo-controlled randomised study of the addition of short-course oral prednisolone in treatment of acute respiratory exacerbations in children with cystic fibrosis [abstract]. In: Proceedings of 22nd European Cystic Fibrosis Conference, 1998 June 13-18; Berlin. 1998:79. NyamugunduruG , DesaiM , WellerP , SpencerDA . The effect of oral prednisolone on serum interleukin-8 concentrations in acute respiratory exacerbations in children with cystic fibrosis [abstract]. In: Proceedings of 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm. Stockholm, 2000:183. ">Nyamugunduru 1998</a>). To our knowledge, this is not yet published. The RCT seems to be eligible for inclusion in the review; however, the information in the abstract is insufficient for assessing methodological quality. The lung function data are not presented in a format which can be aggregated with existing included data. We have written again to the authors for further information. </p> </section> </section> <div class="figures-list"> <div class="figure" id="CD000407-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/urn:x-wiley:14651858:media:CD000407:CD000407-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 1: Absolute change in per cent predicted FEV1" data-id="CD000407-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_t/tCD000407-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 1: Absolute change in per cent predicted FEV1 </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#CD000407-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000407-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/urn:x-wiley:14651858:media:CD000407:CD000407-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 2: Absolute change in per cent predicted FVC" data-id="CD000407-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_t/tCD000407-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 2: Absolute change in per cent predicted FVC </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#CD000407-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000407-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/urn:x-wiley:14651858:media:CD000407:CD000407-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 3: Growth retardation (at 4 years)" data-id="CD000407-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_t/tCD000407-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 3: Growth retardation (at 4 years) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#CD000407-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000407-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/urn:x-wiley:14651858:media:CD000407:CD000407-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 4: Height at age over 18 years (boys)" data-id="CD000407-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_t/tCD000407-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 4: Height at age over 18 years (boys) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#CD000407-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000407-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/urn:x-wiley:14651858:media:CD000407:CD000407-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 5: Height at over 18 years (girls)" data-id="CD000407-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_t/tCD000407-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 5: Height at over 18 years (girls) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#CD000407-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000407-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/urn:x-wiley:14651858:media:CD000407:CD000407-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 6: Absolute change in weight (kg)" data-id="CD000407-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_t/tCD000407-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 6: Absolute change in weight (kg) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#CD000407-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000407-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/urn:x-wiley:14651858:media:CD000407:CD000407-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 7: Weight at over 18 years (boys)" data-id="CD000407-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_t/tCD000407-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 7: Weight at over 18 years (boys) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#CD000407-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000407-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/urn:x-wiley:14651858:media:CD000407:CD000407-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 8: Weight at over 18 years (girls)" data-id="CD000407-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_t/tCD000407-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 8: Weight at over 18 years (girls) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#CD000407-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000407-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/urn:x-wiley:14651858:media:CD000407:CD000407-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 9: Adverse events" data-id="CD000407-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_t/tCD000407-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 9: Adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#CD000407-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000407-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/urn:x-wiley:14651858:media:CD000407:CD000407-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 10: Mortality" data-id="CD000407-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_t/tCD000407-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Oral corticosteroids (any dose) versus placebo, Outcome 10: Mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#CD000407-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/media/CDSR/CD000407/image_n/nCD000407-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD000407-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Long‐term growth ‐ follow up data at 4 years (Auerbach 1985)</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Time</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Group I</b> </p> <p><b>n = 9</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Group II</b> </p> <p><b>n = 5</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Group III</b> </p> <p><b>n = 10</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Group IV</b> </p> <p><b>n = 6</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>End of study (4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Follow up (10 yrs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>Group I: originally randomised to steroids for 4 years, continued on steroids for mean (SD) 9.5 (1.2) years<br/>Group II: originally randomised to steroids for 4 years, ceased taking steroids after mean (SD) 4.5 (0.46) years<br/>Group III: originally randomised to placebo for 4 years, 5 in this group never received steroids and 5 received variable doses of steroids for mean (SD) 0.6 (0.3) years<br/>Group IV: originally randomised to placebo for 4 years, subsequently received steroids for mean (SD) 3.6 (1.2) years<br/>SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Long‐term growth ‐ follow up data at 4 years (Auerbach 1985)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/full#CD000407-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000407-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral corticosteroids (any dose) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Absolute change in per cent predicted FEV1 <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Up to 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.70 [2.32, 15.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.2 Up to 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.10 [0.45, 15.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Absolute change in per cent predicted FVC <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Up to 2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>12.81 [4.73, 20.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Up to 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.70 [‐2.12, 15.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Growth retardation (at 4 years) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 1 mg prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 2 mg prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Height at age over 18 years (boys) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 1 mg prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 2 mg prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Height at over 18 years (girls) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.1 1 mg prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5.2 2 mg prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Absolute change in weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 Up to 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Weight at over 18 years (boys) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 1 mg prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 2 mg prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Weight at over 18 years (girls) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 1 mg prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 2 mg prednisone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.1 Cataracts (1 mg prednisone) (up to 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.2 Cateracts (2 mg prednisone) (up to 3 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.3 Diabetes mellitus (1 mg prednisone) (up to 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.4 Diabetes mellitus (2 mg prednisone) (up to 3 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.5 Glucosoria (1 mg prednisone) (up to 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.6 Glucosoria (2 mg prednisone) (up to 3 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.7 Hyperglycemia (1 mg prednisone) (up to 4 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9.8 Hyperglycemia (2 mg prednisone) (up to 3 years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10.1 At 4 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Oral corticosteroids (any dose) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000407.pub4/references#CD000407-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000407.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD000407-note-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD000407-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000407-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD000407-note-0006">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000407\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000407\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000407\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000407\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000407\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000407.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000407.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000407.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000407.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000407.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725177795"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000407.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725177801"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000407.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e74df59ea1be5',t:'MTc0MDcyNTE3OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 